Loading
Life sciences · Journal article
Journal of Drug Delivery and Therapeutics · September 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Antimicrobial resistance (AMR) is a rapidly escalating global health crisis that threatens the effective treatment of infectious diseases. The emergence of multidrug-resistant (MDR) pathogens, coupled with the declining discovery of new antibiotics, has necessitated the development of innovative therapeutic strategies. Nanotechnology has emerged as a promising approach owing to its unique physicochemical properties, enabling targeted drug delivery, improved antimicrobial efficacy, enhanced biofilm penetration, and reduced systemic toxicity. This review aims to summarize recent advances in nanotechnology-based strategies for combating AMR, highlighting the mechanisms of action, therapeutic applications, current research progress, and future translational prospects. A comprehensive literature search was performed using PubMed, Scopus, Web of Science, and Google Scholar to identify relevant peer-reviewed articles published in recent years. Studies focusing on nanoparticle-based antimicrobial therapies, drug delivery systems, biofilm-targeting approaches, and clinical advancements were critically evaluated. Various nanoplatforms, including metallic, polymeric, lipid-based, and carbon-based nanoparticles, have demonstrated significant potential in overcoming conventional resistance mechanisms through targeted drug delivery, membrane disruption, reactive oxygen species generation, and controlled drug release. Additionally, nanotechnology enhances antibiotic stability, improves intracellular drug accumulation, and facilitates combination therapies. Despite promising preclinical outcomes, challenges related to toxicity, large-scale manufacturing, regulatory approval, and long-term safety remain barriers to clinical translation. Nanotechnology offers a transformative strategy to address antimicrobial resistance by improving therapeutic efficacy and minimizing resistance development. Continued interdisciplinary research, standardized safety evaluations, and well-designed clinical studies are essential to accelerate the successful clinical implementation of nano-enabled antimicrobial therapies. Keywords: Antimicrobial resistance; Nanomedicine; Nanoparticle-based drug delivery; Biofilm inhibition; Precision antimicrobial therapy.